Parkinson Disease
U.S. FDA approves Azilect to treat Parkinson disease
Published in Medical Letter on the CDC and FDA, June 14th, 2006
The drug is approved for use as initial monotherapy in early PD and as adjunct therapy to levodopa in moderate-to-advanced disease. It is expected to become available later this year in two dosage strengths.
"Three placebo-controlled clinical trials demonstrated that rasagiline (Azilect) showed positive effects on motor impairments and activities of daily living in early PD and in moderate-to-advanced stage patients, and was well tolerated," said Ira Shoulson, MD, professor of neurology at the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Addiction Medicine
Unintentional prescription drug overdose deaths increase in New Mexico - Diabetes Epidemiology
Diabetes incidence is increasing in U.S. adults - Food Safety
Method to quantify tetrabromotetrachloro-fluorescein analog in color additives is developed - Hepatitis B Outbreak
Methamphetamine injectors are at high risk for hepatitis B virus infection - Streptococcal Vaccine
Opsonophagocytic assays to identify Streptococcus pneumoniae antibodies were evaluated - Adenovirus Vaccine
Adenoviral respiratory illness in U.S. military recruits is increasing - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
